Cystic Fibrosis (CF) Clinical Trial
Official title:
Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Three Dosage Regimens of MP-376 Solution for Inhalation Given for 28 Days to Stable CF Patients
Verified date | January 2018 |
Source | Horizon Pharma USA, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which has been particularly problematic to eradicate and been implicated as the major cause of morbidity and mortality in CF patients. Aerosol delivery of antibiotics directly to the lung increases the local concentrations of antibiotic at the site of infection resulting in improved antimicrobial effects compared to systemic administration. Bacterial resistance to current aerosol antibiotic treatments indicate a need for improved therapies to treat CF patients with pulmonary infections caused by multi-drug resistant Pseudomonas aeruginosa and other bacteria. High concentrations of MP-376 delivered directly to the lung are projected to have antimicrobial effects on even the most resistant organisms.
Status | Completed |
Enrollment | 151 |
Est. completion date | June 2009 |
Est. primary completion date | June 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years and older |
Eligibility |
Inclusion Criteria (selected): - > 16 years of age - Confirmed Diagnosis of Cystic Fibrosis - Positive sputum culture for P. aeruginosa within the past 18 months - Patients are able to elicit a forced expiratory volume in 1 second (FEV1) >/= 25% but </= 85% of predicted value at screening - Have received at least 3 courses of inhaled antimicrobials over the preceding 12 months - Clinically stable with no changes in health status within the last 30 days - Able to reproducibly produce sputum and perform spirometry Exclusion Criteria (selected): - Use of any nebulized or systemic antibiotics within 30 days prior to baseline - History of hypersensitivity to fluoroquinolones or intolerance with aerosol medication - Evidence of acute upper within 10 days or lower respiratory infections within 30 days prior to dosing - Creatine clearance < 50mg/ml, aspartate transaminase (AST), alanine transaminase (ALT) or total bilirubin >/= 3 x upper limit of normal (ULN) at Screening |
Country | Name | City | State |
---|---|---|---|
United States | Childrens Hospital | Los Angeles | California |
United States | Oklahoma CF Center | Oklahoma City | Oklahoma |
Lead Sponsor | Collaborator |
---|---|
Horizon Pharma USA, Inc. |
United States, Germany, Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in P. Aeruginosa Density | Patients were required to cough deeply and then spit sputum into a sterile container. The bacteria contained in the sputum sample was incubated in a laboratory and the number of P. aeruginosa colony forming units per gram of sputum (CFU/g) was determined. The difference in CFUs/g were then compared from baseline to the conclusion of the 28 day treatment period | from baseline to end of treatment (28 days) | |
Secondary | Time to Administration of Other Anti-pseudomonal Antimicrobials | Time to administration of other anti-pseudomonal antimicrobials in patients with at least one of the following: decreased exercise tolerance, increased cough, increased sputum/chest congestion, or decreased appetite; 25th percentile data reported | from baseline until final study visit (up to 56 days) | |
Secondary | Percent Change in Forced Expiratory Volume in 1 Second (FEV1) | Percent change in the amount of air the patient could exhale in 1 second | from baseline to end of the 28-day treatment period (28 days) | |
Secondary | Change in FEV1 Percent Predicted | Change in the predicted percent of air the patient could exhale in one second | from baseline to the end of the treatment 28-day treatment period (28 days) | |
Secondary | Changes in Respiratory Domain Scores of Cystic Fibrosis Questionnaire - Revised (CFQ-R) | Change in the score from 0 to 100 that a patient reports for their respiratory symptoms in the CFQ-R. An increase in score illustrates an improvement in symptoms. An increase of 4 or more is considered clinically significant | from baseline to the end of the 28-day treatment period (28 days) | |
Secondary | Changes in Susceptability Patterns of Isolated Organisms | All isolates of P. aeruginosa cultures grown from patient sputum samples were evaluated to see whether the minimum concentration of levofloxacin needed to inhibit growth of the bacteria (i.e., minimum inhibitory concentration; MIC) had increased; 2. The MIC50 and MIC90 values were calculated as the 50th percentile value and the 90th percentile value, respectively. Note that percentile values between dilution values were rounded up to the nearest dilution value | from baseline until the end of the 28-day treatment period (28 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04853368 -
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis
|
Phase 2 | |
Terminated |
NCT03234387 -
A CFit Study - Baseline
|
||
Completed |
NCT03445793 -
: TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)
|
||
Completed |
NCT02778750 -
Evaluation Of The Pan-microbiome and Host Immune Response in CF
|
||
Terminated |
NCT03597347 -
Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection
|
Phase 2 | |
Recruiting |
NCT05818319 -
Cystic Fibrosis in the Kidney: Monitoring the Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in Urine After a Short Pause of Therapy
|
N/A | |
Completed |
NCT04375878 -
OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis
|
Phase 2 | |
Withdrawn |
NCT01951833 -
Long Term Significance (Survival) of LCI in Patients With Cystic Fibrosis
|
N/A | |
Completed |
NCT03746483 -
OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
|
Phase 2 | |
Completed |
NCT02163681 -
MRI for Non-Invasive Imaging in Neonates and Children
|
N/A | |
Completed |
NCT02036879 -
Gender Disparity and Hormones in Cystic Fibrosis
|
Early Phase 1 | |
Completed |
NCT02605590 -
Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers
|
Phase 1 | |
Recruiting |
NCT01851642 -
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
|